Background: Two therapeutic options are currently available for patients with mild-to-
moderate idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. To date, there is …

We assessed safety and tolerability of treatment with pirfenidone (1602–2403 mg· day− 1)
and nintedanib (200–300 mg· day− 1) in patients with idiopathic pulmonary fibrosis (IPF) …

Background Real-life data on the use of pirfenidone and nintedanib to treat patients with
idiopathic pulmonary fibrosis (IPF) are still scarce. Methods We compared the efficacy of …

Background: Nintedanib slows disease progression in patients with Idiopathic Pulmonary
Fibrosis (IPF) by reducing decline in Forced Vital Capacity (FVC). The effects of nintedanib …

Background: The efficacy and effectiveness of nintedanib as a first-line therapy in idiopathic
pulmonary fibrosis (IPF) patients have been demonstrated by clinical trials and real-life …

Introduction The INPULSIS-ON trial demonstrated that nintedanib reduced decline in forced
vital capacity (FVC) and low pulmonary function (% FVC< 50%) of patients with idiopathic …

Background: Nintedanib, an oral tyrosine kinase inhibitor, has been shown to slow down the
progression of idiopathic pulmonary fibrosis (IPF) in two randomised placebo-controlled …

Background Phase 3 trials have shown that nintedanib reduces the decline in forced vital
capacity (FVC) in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF) with …

Background: Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF)
and has been shown to slow disease progression by reducing annual lung function decline …

Rationale: Nintedanib and pirfenidone slow the progression of idiopathic pulmonary fibrosis
(IPF), but the disease continues to progress. More data are needed on the safety and …